Breast cancer nursing: a complete reference for nursing students

Breast cancer is the most commonly diagnosed cancer in women in the United States (after skin cancer), with approximately 1 in 8 women facing a diagnosis over their lifetime. For nursing students, breast cancer represents one of the most clinically complex conditions you will encounter — a disease spanning medical-surgical floors, oncology units, procedural areas, and outpatient infusion centers. The nursing care spans surgical recovery, lymphedema prevention, hazardous drug administration, cardiac monitoring for targeted therapies, and extensive psychosocial support.

This reference covers everything you need for NCLEX preparation, clinical rotations, and practice: molecular subtypes, staging, diagnostics, surgical nursing care, lymphedema management, chemotherapy and targeted therapy nursing priorities, endocrine therapy, oncologic emergencies specific to breast cancer, and psychosocial care.

Use this alongside the oncology nursing reference for general chemotherapy safety principles and oncologic emergencies, and the lymphedema nursing reference for in-depth lymphedema management.

Quick reference: breast cancer molecular subtypes

Understanding molecular subtypes is essential — they determine treatment approach and prognosis. The four major subtypes are defined by receptor expression.

NCLEX tip: Triple-negative breast cancer (TNBC) has no targeted therapies (no estrogen receptor, no HER2). Chemotherapy is the only systemic option, making it the hardest to treat and the subtype with the worst prognosis.

Pathophysiology and epidemiology

Incidence and risk factors

Breast cancer is the second leading cause of cancer death in women in the US (after lung cancer). Key epidemiological facts for NCLEX:

• Lifetime risk: Approximately 1 in 8 (12.5%) US women will develop breast cancer
• BRCA1 mutations: Confer a 50–85% lifetime risk of breast cancer; predominantly produce ER-negative, triple-negative tumors. Also increases ovarian cancer risk substantially.
• BRCA2 mutations: Similar elevated lifetime risk (45–85%); predominantly produce ER-positive tumors. Also associated with male breast cancer and ovarian cancer.
• Other high-risk genes: PALB2, CHEK2, ATM — genetic counseling is recommended when identified

Additional risk factors include: increasing age, dense breast tissue (limits mammogram sensitivity), prolonged estrogen exposure (early menarche, late menopause, nulliparity, hormone replacement therapy), prior chest radiation (especially in adolescence, as in Hodgkin lymphoma survivors), first-degree family history, prior breast biopsies showing atypical hyperplasia, and alcohol consumption.

Protective factors: breastfeeding, early first full-term pregnancy, bilateral oophorectomy in BRCA carriers.

Tumor types

Ductal tumors arise from the milk duct epithelium. Invasive ductal carcinoma (IDC) is the most common breast cancer overall, representing approximately 70–80% of cases. Ductal carcinoma in situ (DCIS) is the non-invasive precursor.

Lobular tumors arise from the milk-producing lobules. Invasive lobular carcinoma (ILC) accounts for approximately 10–15% of cases and has a characteristic pattern of single-file cell infiltration. ILC can be harder to detect on mammogram because it does not always form a discrete mass.

In situ vs invasive: In situ (DCIS, LCIS) means cells are abnormal but have not broken through the basement membrane. Invasive cancer has penetrated the basement membrane and can potentially spread to lymph nodes and distant sites.

Staging: the AJCC TNM system

Breast cancer staging combines the TNM classification with biomarker information (ER, PR, HER2, and tumor grade) in the updated AJCC 8th Edition. For NCLEX purposes, the anatomic staging summary below covers what you need.

Key Stage IV facts: Bone is the most common site of distant metastasis in breast cancer. Patients with bone-only metastases can survive for years with appropriate treatment (bisphosphonates, endocrine therapy). Brain and liver metastases carry a poorer short-term prognosis.

Diagnostics

Screening mammography

Screening guidelines differ between major organizations — this is a frequent NCLEX topic because nurses must be able to explain the differences to patients:

• American Cancer Society (ACS): Annual mammography starting at age 40. High-risk women (BRCA+, prior chest radiation) should begin annual MRI + mammogram at age 30.
• USPSTF: Biennial (every 2 years) mammography for women ages 50–74; shared decision-making for ages 40–49.
• For NCLEX: Know that the ACS recommends annual screening starting at 40. The difference between annual and biennial is a common distractor question.

Diagnostic workup sequence

1. Diagnostic mammogram — differs from screening: multiple views, magnification, targeted to area of concern
2. Breast ultrasound — distinguishes solid masses from cysts; used to guide biopsy; preferred for women under 30 and during pregnancy
3. Breast MRI — recommended for high-risk women (BRCA carriers), dense breasts, extent-of-disease assessment; not used for routine screening in average-risk women
4. Core needle biopsy (CNB) — the gold standard for tissue diagnosis; provides receptor status (ER, PR, HER2) and grade. Fine needle aspiration (FNA) provides cytology only — not sufficient for definitive diagnosis.
5. Sentinel lymph node biopsy (SLNB) — blue dye and/or radiotracer injected to identify first draining lymph node(s); if negative, full axillary dissection may be avoided
6. Genetic testing — BRCA1/2, PALB2, CHEK2 — recommended for patients with family history, young onset (<45), triple-negative histology, or Ashkenazi Jewish ancestry

Treatment overview

Surgical options

Breast reconstruction options:

• Tissue expander + implant: Two-stage approach; most common; expander placed at mastectomy, gradually filled, then exchanged for permanent implant
• TRAM flap (transverse rectus abdominis myocutaneous): Abdominal skin and fat with rectus muscle pedicle; abdominal strength reduction is a notable long-term effect
• DIEP flap (deep inferior epigastric perforator): Similar to TRAM but spares the rectus muscle; technically demanding; preferred when abdominal muscle preservation matters
• Latissimus dorsi flap: Back tissue rotated forward; often used with implant; good for women with prior abdominal surgery

Radiation therapy

• Whole-breast radiation (WBI): Standard after lumpectomy; reduces local recurrence by approximately 50%; typically 5–6 weeks of daily fractions
• Accelerated partial-breast irradiation (APBI): Radiation targeted to the tumor bed only; shorter course (1–2 weeks); selected low-risk early-stage patients
• Post-mastectomy radiation (PMRT): Recommended for ≥4 positive lymph nodes, T3/T4 tumors, close or positive surgical margins; reduces local recurrence and improves survival in high-risk cases

Chemotherapy regimens and nursing considerations

The standard chemotherapy approach for breast cancer depends on subtype and stage. AC-T (doxorubicin + cyclophosphamide followed by paclitaxel) is the most common regimen for high-risk or TNBC.

Neutropenia nadir and infection risk

Chemotherapy causes a predictable nadir — the lowest point of neutrophil count — typically occurring day 10–14 after administration. Teach patients to monitor for fever and call their oncology team immediately for:

• Temperature ≥100.4°F (38°C) — even a single reading
• Shaking chills, rigors
• Unusual redness, swelling, or pain at any site

Growth factors (G-CSF: filgrastim, pegfilgrastim) may be prescribed to shorten the nadir and reduce infection risk.

Nursing priorities: surgical care

Pre-operative assessment and teaching

Before mastectomy or lumpectomy, nursing priorities include:

• Baseline neurovascular assessment of the upper extremity on the operative side
• Teach arm exercises to begin post-operatively: hand pumping, elbow bends, shoulder rolls, and progressive range-of-motion exercises starting day 1–2 post-op
• Drain management education — Jackson-Pratt drains are placed during most mastectomies; teach the patient to empty the bulb, measure and record output, and recognize signs of infection
• Body image counseling — refer to oncology social work before surgery for patients undergoing mastectomy, not just after; pre-operative counseling improves post-operative adjustment
• Explain post-operative arm precautions — the affected arm will require lifelong precautions if lymph nodes are removed

Post-operative assessment

After mastectomy or lumpectomy with lymph node surgery, assess for:

• Seroma — fluid accumulation under the flap or in the axilla; the most common post-mastectomy complication; presents as swelling, fullness, or fluctuance; may require aspiration
• Hematoma — blood accumulation; presents as firm, painful swelling with possible skin discoloration; may require surgical evacuation if large
• Wound infection — warmth, erythema, purulent drainage, fever; monitor incision at every assessment
• Skin flap necrosis — discoloration (dark purple, then black) of the mastectomy flap; risk factors include smoking, diabetes, tension on the flap; report early
• Nerve injury — intercostobrachial nerve (numbness/tingling inner upper arm) is common after ALND and may be permanent

Positioning and limb precautions

• Elevate the affected arm above heart level when in bed to promote lymphatic drainage
• Position arm on a pillow at the patient’s side, not across the body
• Do NOT take blood pressure on the affected arm — causes compression that impairs lymphatic flow
• Do NOT perform venipuncture or IV insertion in the affected arm — even a small puncture can trigger or worsen lymphedema
• Do NOT draw blood from the affected arm — same rationale

These precautions apply for life, not just during the hospital stay.

Jackson-Pratt drain management

Jackson-Pratt (JP) drains collect fluid from the operative site. Nursing care includes:

• Empty the JP bulb and re-establish suction (compress and close with cap compressed) every shift and as needed
• Measure and document drainage output each emptying — note color and character (serosanguineous early, clearing over days)
• Milking or stripping the drain tubing per surgeon order if clots occlude the tube
• Monitor for signs of infection at the drain site
• Removal criteria: Most surgeons remove JP drains when output is less than 30 mL over 24 hours for two consecutive days. This is an NCLEX-tested threshold.

Phantom breast syndrome

Some patients experience phantom breast sensations — tingling, pain, or the sensation that the breast is still present — after mastectomy. This is a normal neurological phenomenon (similar to phantom limb after amputation). Nursing interventions include normalizing the experience, referral to pain management if severe, and mirror therapy or sensory retraining.

Lymphedema prevention and management

Lymphedema is abnormal accumulation of lymphatic fluid in the affected limb due to disrupted lymphatic drainage. It is one of the most impactful long-term complications of breast cancer treatment and a major nursing priority.

Risk stratification by surgical approach

• Sentinel lymph node biopsy (SLNB) only: Lifetime lymphedema risk approximately 5–7%
• Axillary lymph node dissection (ALND): Lifetime lymphedema risk approximately 20–30%
• ALND + radiation to the axilla: Risk increases further, up to 40% in some series

Lifelong precautions

Lymphedema precautions are not temporary — they apply for the remainder of the patient’s life because the lymphatic impairment is permanent. Every nursing assessment should reinforce:

• No blood pressure measurements on the affected arm
• No IV access, injections, or blood draws on the affected arm
• Protect the arm from cuts, burns, insect bites, and puncture wounds
• Wear gloves for gardening, cooking, and cleaning with harsh chemicals
• Avoid carrying heavy bags on the affected shoulder
• Wear compression garments during air travel (low cabin pressure increases lymphedema risk)
• Report any arm swelling, heaviness, tightness, or skin changes promptly

Signs and symptoms of lymphedema

Early lymphedema: arm feels “heavy,” full, or tight; clothing and rings feel tighter; skin has slight pitting when pressed; patient may notice intermittent swelling that resolves overnight.

Established lymphedema: persistent non-pitting edema; skin becomes thickened and fibrotic over time; recurrent cellulitis is a complication.

Complete decongestive therapy (CDT)

CDT is the gold-standard treatment for lymphedema and has four components:

1. Manual lymphatic drainage (MLD) — specialized massage technique by a certified lymphedema therapist; redirects lymph flow to unaffected lymphatic territories
2. Compression bandaging — short-stretch bandages applied by therapist to reduce limb volume during the intensive treatment phase
3. Therapeutic exercises — limb exercises performed while wearing compression; activates the lymphatic pump
4. Meticulous skin care — moisturize to prevent skin breakdown; treat any wounds or infections promptly to prevent cellulitis

Compression garments (custom-fitted sleeves and gauntlets) are worn during maintenance phase for sustained control.

For complete lymphedema assessment and management, see the lymphedema nursing reference.

HER2-targeted therapy nursing care

Trastuzumab (Herceptin)

Trastuzumab is a monoclonal antibody targeting HER2. It has transformed outcomes for HER2+ breast cancer — but requires careful cardiac monitoring because HER2 receptors are also expressed in cardiomyocytes.

Cardiac monitoring protocol:

• Baseline LVEF (echocardiogram or MUGA scan) before initiating trastuzumab
• LVEF reassessment every 3 months during treatment
• Hold trastuzumab if: LVEF drops ≥10 percentage points below baseline AND falls below 50%, OR LVEF falls below 40% regardless of change from baseline
• Unlike doxorubicin cardiotoxicity (cumulative and often irreversible), trastuzumab cardiotoxicity is non-cumulative and frequently reversible on drug discontinuation

Infusion reactions:

• Most common during the first infusion — chills, fever, nausea, hypotension, bronchospasm
• Slow the infusion rate at first sign of reaction; do not restart if severe
• Subsequent infusions are generally well tolerated

Pertuzumab (Perjeta) is frequently combined with trastuzumab for HER2+ metastatic breast cancer and in the neoadjuvant setting (dual HER2 blockade). It does not add significant additional cardiotoxicity beyond trastuzumab.

Ado-trastuzumab emtansine (T-DM1, Kadcyla)

T-DM1 is an antibody-drug conjugate that delivers a cytotoxic payload (emtansine, a microtubule inhibitor) directly to HER2-expressing cells. It is used for patients with HER2+ early breast cancer who have residual invasive disease after neoadjuvant therapy.

Key nursing priorities:

• Thrombocytopenia: Most significant toxicity; monitor platelet count before each 3-week cycle; nadir typically around day 8; hold for platelets <100,000/mm³; instruct patient to avoid NSAIDs, limit bleeding risk
• Hepatotoxicity: Monitor AST, ALT, bilirubin; dose hold or reduction for elevated LFTs
• Name confusion alert: T-DM1 and trastuzumab are different drugs with different indications, doses, and toxicity profiles. Fatal medication errors have occurred from confusion between the two. Always verify the exact drug name.

Tucatinib (Tukysa)

Tucatinib is an oral HER2-specific tyrosine kinase inhibitor used in combination with trastuzumab and capecitabine for HER2+ metastatic breast cancer that has progressed on at least one prior HER2-targeted regimen. Notable for activity in brain metastases — an important clinical distinction. Key nursing concern: hepatotoxicity and diarrhea.

Endocrine therapy nursing care

Endocrine (hormone) therapy is the backbone of treatment for ER+/PR+ breast cancer. It works by depriving cancer cells of estrogen signaling.

Tamoxifen

Tamoxifen is a selective estrogen receptor modulator (SERM) — it blocks estrogen receptors in breast tissue but acts as a partial agonist in other tissues (bone, uterus). It is used in premenopausal women and some postmenopausal women. Standard duration: 5–10 years.

Nursing priorities and patient teaching:

• Thromboembolic events: Tamoxifen increases the risk of DVT and PE — teach patients to report leg pain, swelling, chest pain, or sudden shortness of breath immediately. See the DVT nursing reference for assessment and management.
• Endometrial cancer: Tamoxifen’s agonist effect on uterine tissue increases endometrial cancer risk (approximately 2–3× baseline). Teach patients to report any abnormal uterine bleeding — this should always be investigated.
• Menopausal symptoms: Hot flashes, vaginal dryness, mood changes — common and often the primary reason for non-adherence. Discuss management options.
• Drug interactions: CYP2D6 inhibitors reduce tamoxifen’s conversion to its active metabolite (endoxifen), reducing efficacy. Avoid paroxetine and fluoxetine with tamoxifen — use sertraline or venlafaxine instead for hot flashes or depression.

Aromatase inhibitors

Aromatase inhibitors (AIs) — anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin) — block the conversion of androgens to estrogen in peripheral tissues. They are first-line endocrine therapy for postmenopausal women with ER+ breast cancer and are more effective than tamoxifen in the postmenopausal setting.

Aromatase inhibitors work only in postmenopausal women — in premenopausal women, ovarian estrogen production overwhelms the peripheral blockade. Premenopausal women who switch to an AI must first undergo ovarian suppression (goserelin injection).

Nursing priorities and patient teaching:

• Arthralgia/joint pain: The most common reason for AI discontinuation — affects up to 50% of patients. It is the number one compliance barrier. Discuss in advance; reassure that symptoms often improve after the first few months; omega-3 supplementation and physical activity may help; can try switching to a different AI.
• Bone loss: AIs suppress estrogen-dependent bone maintenance. All patients starting AI therapy should have a baseline DEXA scan; calcium (1,000–1,200 mg/day) and vitamin D (800–1,000 IU/day) supplementation is standard; bisphosphonate therapy added if T-score drops significantly. See the osteoporosis nursing reference for bone loss assessment and management.
• Cardiovascular effects: Hyperlipidemia may worsen on AIs (unlike tamoxifen, which has some cardioprotective effects); monitor lipid panels.

CDK4/6 inhibitors

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors — palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Verzenio) — are combined with an aromatase inhibitor or fulvestrant for hormone receptor-positive, HER2-negative metastatic breast cancer. They have dramatically extended progression-free and overall survival in this setting.

Shared toxicities:

• Neutropenia: Dose-limiting toxicity for all three agents; monitor CBC at baseline, at day 14 of first two cycles, then at the start of each subsequent cycle; absolute neutrophil count guides dose adjustments
• Fatigue: Common across all three agents

Agent-specific distinctions:

• Ribociclib: QTc prolongation — baseline ECG required; avoid concurrent QTc-prolonging medications; repeat ECG at day 14 of first cycle
• Abemaciclib: Diarrhea is the most prominent GI toxicity (unique vs palbociclib/ribociclib); loperamide prescribed prophylactically at first loose stool
• Palbociclib: Primarily neutropenia and fatigue; less GI toxicity than abemaciclib

Oncologic emergencies specific to breast cancer

Hypercalcemia of malignancy

Breast cancer with bone metastases is one of the most common causes of malignant hypercalcemia. Normal total serum calcium is 8.5–10.5 mg/dL; values above 10.5 mg/dL in a cancer patient warrant assessment.

Clinical features follow “bones, stones, groans, and psychic moans”: bone pain, kidney stones/polyuria/polydipsia, nausea/vomiting/constipation, confusion/lethargy.

Nursing priorities:

• IV hydration with normal saline is first-line treatment — promotes renal calcium excretion; monitor fluid balance
• Bisphosphonates (zoledronic acid preferred) or denosumab IV — peak effect takes 24–48 hours; monitor renal function before dosing
• Calcitonin may provide faster but shorter-lived calcium lowering for severe, symptomatic hypercalcemia
• Continuous cardiac monitoring — hypercalcemia shortens the QT interval and can cause arrhythmias

Spinal cord compression

Breast cancer is among the cancers most commonly causing epidural spinal cord compression (along with lung and prostate). Vertebral metastases expand into the epidural space, compressing the cord.

Early warning signs: New or worsening back pain is the sentinel symptom — present in 83–95% of cases before neurological deficits. Pain may worsen when lying flat or with Valsalva.

Neurological emergency signs: Lower extremity weakness, sensory changes, urinary retention, bowel dysfunction, or paralysis.

Nursing priorities:

• Report any new back pain with neurological symptoms to the provider immediately
• Log roll for all position changes until spinal stability is confirmed on imaging
• Dexamethasone (corticosteroids) administered urgently to reduce cord edema
• Urgent MRI is the diagnostic standard
• Monitor for urinary retention; catheterize as ordered
• Document baseline neurological exam; reassess every 2–4 hours for changes

Brain metastases

Brain metastases occur in approximately 10–15% of breast cancer patients overall, but in up to 30–50% of HER2+ and TNBC patients. The brain is a “sanctuary site” — many systemic therapies do not cross the blood-brain barrier.

Signs and symptoms: Headache (worsens with activity, bending forward, or coughing), focal neurological deficits (weakness, speech difficulty, vision changes), personality changes, seizures.

Nursing priorities:

• Report new or worsening headache with neurological changes immediately
• Dexamethasone to reduce cerebral edema — monitor blood glucose (steroid-induced hyperglycemia)
• Seizure precautions if seizure occurs or is anticipated
• Safety assessment — fall risk, aspiration risk, orientation
• MRI is the diagnostic standard; treatment options include stereotactic radiosurgery (SRS), whole-brain radiation therapy (WBRT), or surgery depending on number and size of lesions

Pathologic fractures

Breast cancer bone metastases weaken skeletal integrity, placing patients at risk for fractures with minimal trauma. The femur, humerus, spine, and ribs are most vulnerable.

Clinical presentation: Pain that worsens with weight-bearing (long bones); sudden increase in pain with any movement.

Nursing priorities:

• Handle affected extremities with care; use lift equipment; log roll for spinal lesions
• Immobilize suspected fractures; report immediately
• Bone-modifying agents (denosumab, zoledronic acid) reduce skeletal-related events — given regularly for patients with bone metastases; monitor calcium, phosphate, magnesium, and renal function before each dose
• Monitor for osteonecrosis of the jaw (ONJ) with long-term bisphosphonate use — dental evaluation before starting therapy; avoid invasive dental procedures during treatment

Psychosocial nursing care

Body image and identity

Mastectomy, alopecia, weight changes, and menopausal symptoms can profoundly affect body image and self-concept. Nursing priorities:

• Assess body image and self-concept using open-ended questions — do not assume the patient’s reaction
• Refer to oncology social work before and after surgery for patients undergoing mastectomy
• Discuss options for post-mastectomy lingerie, external breast prosthetics, and wigs or head coverings before alopecia begins (not after)
• Connect patients with peer support programs (e.g., American Cancer Society Reach to Recovery)

Depression and anxiety

Depression and anxiety affect 25–50% of breast cancer patients at some point during the trajectory of their illness. Routine screening is an evidence-based nursing practice:

• Use validated screening tools: PHQ-9 for depression, GAD-7 for anxiety
• A score of ≥10 on the PHQ-9 indicates moderate-to-severe depression requiring clinical evaluation
• Refer to oncology psychology, psychiatry, or social work as appropriate
• Antidepressant selection requires coordination with the oncology team — avoid CYP2D6 inhibitors (paroxetine, fluoxetine) in patients on tamoxifen

Sexual health

Endocrine therapy causes vaginal dryness, decreased libido, and dyspareunia (painful intercourse) in premenopausal and postmenopausal women alike. These symptoms significantly impact quality of life and contribute to therapy non-adherence:

• Assess sexual health concerns as part of routine nursing assessment — many patients do not raise it unless asked
• Water-based lubricants and vaginal moisturizers are first-line, non-hormonal options
• Pelvic floor physical therapy has strong evidence for dyspareunia
• Topical vaginal estrogen (low-dose) is generally considered safe for ER+ breast cancer patients — but this requires oncology team input

Fertility preservation

Premenopausal women starting chemotherapy face chemotherapy-related gonadotoxicity and potential early menopause. The standard of care includes fertility counseling before starting chemotherapy:

• Embryo cryopreservation (most effective, requires a partner or sperm donor) or oocyte (egg) freezing
• Ovarian suppression with a GnRH agonist (e.g., goserelin/Zoladex) during chemotherapy may reduce ovarian damage — discuss with oncology and reproductive endocrinology
• Ovarian tissue cryopreservation is available at some centers

Genetic counseling and family implications

BRCA1/2 mutations have implications beyond the patient — first-degree relatives have a 50% chance of inheriting the mutation:

• All BRCA+ patients should be referred to a certified genetic counselor
• Discuss risk-reduction options: bilateral prophylactic mastectomy (reduces breast cancer risk by ~90%) and bilateral salpingo-oophorectomy (reduces ovarian cancer risk and, if performed before natural menopause, reduces breast cancer risk further)
• Cascade testing for family members is recommended and should be facilitated

NCLEX high-yield bullet points

These are the most commonly tested facts about breast cancer nursing on the NCLEX. Know every one.

• The affected arm after axillary lymph node dissection: no blood pressure, IV access, injections, or blood draws — for life. These precautions do not expire when treatment ends.
• SLNB carries a 5–7% lifetime lymphedema risk; ALND carries a 20–30% lifetime risk. Knowing the difference matters clinically when counseling patients.
• Trastuzumab (Herceptin): Monitor LVEF at baseline and every 3 months. Hold if LVEF drops ≥10 percentage points below baseline AND falls below 50%. Unlike doxorubicin, trastuzumab cardiotoxicity is potentially reversible.
• Doxorubicin: Vesicant — must use a central line or confirmed patent peripheral IV. Cumulative dose limit ~450 mg/m² (standard protocols). Red-colored urine is expected, not hematuria. Baseline and serial cardiac monitoring required.
• Paclitaxel: Premedicate with corticosteroid (dexamethasone) + antihistamine (diphenhydramine) + H2 blocker (famotidine or ranitidine) before each infusion. Infuse slowly — hypersensitivity reactions occur most in the first 10 minutes. Monitor for peripheral neuropathy.
• Cyclophosphamide: Hemorrhagic cystitis is the key toxicity. Prevent with aggressive hydration and mesna for high-dose regimens. Monitor urine for blood.
• Tamoxifen: Increased risk of DVT, PE, and endometrial cancer. Teach patients to report abnormal vaginal bleeding immediately. Avoid paroxetine and fluoxetine (CYP2D6 inhibitors) — they reduce tamoxifen’s active metabolite and clinical efficacy.
• Aromatase inhibitors (anastrozole, letrozole, exemestane): Used in postmenopausal women only. Cause arthralgia/joint pain (most common reason for non-adherence) and bone loss. Monitor bone density; calcium and vitamin D supplementation is standard.
• CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib): Neutropenia is the shared dose-limiting toxicity; monitor CBC every 2 weeks for the first 2 cycles. Ribociclib also prolongs QTc — baseline ECG required. Abemaciclib causes significant diarrhea.
• TNBC (triple-negative): Most aggressive subtype; no hormone receptor or HER2 targets; chemotherapy is the only systemic option. Pembrolizumab is approved for PD-L1-positive metastatic TNBC. PARP inhibitors (olaparib, talazoparib) are options for BRCA-mutated TNBC.
• BRCA1 mutations produce predominantly ER-negative/triple-negative tumors. BRCA2 mutations produce predominantly ER-positive tumors.
• Jackson-Pratt drain removal: Criterion is output less than 30 mL over 24 hours for two consecutive days. This is the NCLEX threshold — memorize it.
• Bone metastases: The most common distant site in breast cancer is bone. Bisphosphonates (zoledronic acid) and denosumab reduce skeletal-related events. Assess for osteonecrosis of the jaw (ONJ) with prolonged bisphosphonate use.
• Neutropenia nadir: Typically day 10–14 after chemotherapy. Teach patients to report any temperature ≥100.4°F (38°C) — this is a medical emergency in a neutropenic patient.
• Radiation skin care: No deodorant on the treated side during radiation; use only radiation oncology-approved products; no heating pads or ice packs; loose clothing over the treatment field; do not remove skin markings.
• Hypercalcemia of malignancy: Breast cancer + bone mets = risk. Treatment is IV normal saline (first-line) + bisphosphonate. Signs: “bones, stones, groans, and psychic moans.” Cardiac monitoring for arrhythmia (shortened QT interval).
• T-DM1 vs trastuzumab: These are different drugs. T-DM1 (ado-trastuzumab emtansine, Kadcyla) is an antibody-drug conjugate with different dosing, toxicities (thrombocytopenia, hepatotoxicity), and indications. Fatal errors have occurred from confusion between these agents — always verify the exact drug name.
• Spinal cord compression: Back pain is the warning sign — report immediately. Neurological deterioration (weakness, bowel/bladder changes) requires urgent MRI and dexamethasone. Log roll for all position changes.

Related references

This article is part of the comprehensive oncology nursing library at NursingSchoolsNearMe.com:

• Oncology nursing reference — general chemotherapy safety, oncologic emergencies, cancer pain, and radiation nursing
• Lymphedema nursing reference — complete decongestive therapy, staging, and long-term management
• Leukemia nursing reference — AML, CLL, ALL: blast crisis, ATRA syndrome, and TLS management
• Lymphoma nursing reference — Hodgkin lymphoma (ABVD, bleomycin toxicity), non-Hodgkin lymphoma (R-CHOP, rituximab), CAR-T nursing
• DVT and PE nursing reference — thromboembolic complications relevant to tamoxifen and cancer patients
• Osteoporosis nursing reference — bone density monitoring, calcium and vitamin D management, bisphosphonate nursing priorities